Lymphoma & Leukaemia Watch 45 – MRD in CLL… what is it and does it matter?
Study Review – GLOW Study update: Long-term efficacy and safety of ibrutinib-venetoclax in first-line CLL
Lymphoma & Leukaemia Research Review, Issue 96
Product Review – Brexucabtagene autoleucel for treating adults with relapsed or refractory B-cell precursor ALL
Lymphoma & Leukaemia Practice Review Issue 2
Associate Professor Shaun Fleming discusses CAR T-cell treatment for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)
https://vimeo.com/1097934669https://vimeo.com/1097934627https://vimeo.com/1097934505https://vimeo.com/1097934433https://vimeo.com/1097934357
Lymphoma & Leukaemia Watch 44 – Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study
